---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005992"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-09-22T23:59:59+00:00"
generated_at: "2026-05-17T06:03:39.399893+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aptose secures $11.9M loan from Hanmi to fund tuspetinib AML study

## Summary
- Amended facility with Hanmi provides up to $11.9M in uncommitted advances through Dec 31, 2025; first advance expected soon.
- Final $1.4M advance received under prior June 2025 facility, totaling $8.5M from that agreement.
- Loan is a related-party transaction; Aptose relies on financial hardship exemption from formal valuation and minority approval.
- Proceeds fund TUSCANY Phase 1/2 trial of tuspetinib + venetoclax + azacitidine in newly diagnosed AML patients.
- Early data showed 9/10 patients responded; 100% CR/CRh at 80mg and 120mg cohorts across adverse mutations.

## SEC filing metadata
- accession: 0001171843-25-005992
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-09-22T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325005992/0001171843-25-005992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325005992/f8k_092225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005992
- JSON: https://secwatch.observer/filing/0001171843-25-005992.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005992.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.